Experienced in Attention Deficit Hyperactivity Disorder (ADHD)

Dr. Robert B. Molpus

Psychiatry
455 W Warren Ave, 
Longwood, FL 
Experienced in Attention Deficit Hyperactivity Disorder (ADHD)
455 W Warren Ave, 
Longwood, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Molpus is a Psychiatrist in Longwood, Florida. Dr. Molpus is rated as an Experienced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). His top area of expertise is Attention Deficit Hyperactivity Disorder (ADHD).

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 3 clinical trials in the study of Attention Deficit Hyperactivity Disorder (ADHD).

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

455 W Warren Ave, Longwood, FL 32750

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: September 08, 2025
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
PROSPER-FM: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
PROSPER-FM: Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Device, Other
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)
An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Genetic, Other
Study Phase: Not Applicable
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
View 9 Less Clinical Trials
Similar Doctors
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Aaron D. Quinlan
Psychiatry
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Aaron D. Quinlan
Psychiatry
225 E 7th St, 
Apopka, FL 
 (9.6 miles away)
407-905-8827
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aaron Quinlan is a Psychiatrist in Apopka, Florida. Dr. Quinlan is rated as an Advanced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). His top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Oppositional Defiant Disorder (ODD), Post-Traumatic Stress Disorder (PTSD), and Generalized Anxiety Disorder (GAD). Dr. Quinlan is currently accepting new patients.

Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Madhurya Polavarapu
Psychiatry
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Madhurya Polavarapu
Psychiatry

Lakeland Regional Health Systems Inc

1324 Lakeland Hill Blvd, 
Lakeland, FL 
 (57.3 miles away)
863-687-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Madhurya Polavarapu is a Psychiatrist in Lakeland, Florida. Dr. Polavarapu is rated as an Advanced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Her top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), Schizophrenia, and Major Depression. Dr. Polavarapu is currently accepting new patients.

Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Kazi W. Ahmad
Psychiatry
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Kazi W. Ahmad
Psychiatry

Personal Recovery Network LLC

260 Lookout Pl, 
Maitland, FL 
 (4.4 miles away)
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Kazi Ahmad is a Psychiatrist in Maitland, Florida. Dr. Ahmad is rated as an Advanced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). His top areas of expertise are Generalized Anxiety Disorder (GAD), Seasonal Affective Disorder (SAD), Major Depression, and Attention Deficit Hyperactivity Disorder (ADHD). Dr. Ahmad is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molpus's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile